血清白细胞介素-35表达水平与前列腺癌全雄激素阻断治疗预后的相关性分析  

Correlation analysis of serum interleukin-35 expression level and prognosis of prostate cancer after total androgen deprivation therapy

作　　者：李永强[1] 宫小勇[1] 郑伟[1] 马宏召 南涛 常莎 Li Yongqiang;Gong Xiaoyong;Zheng Wei;Ma Hongzhao;NanTao;Chang Sha(Department of Urology,The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang,712000,China;不详)

机构地区：[1]陕西中医药大学第二附属医院泌尿外科,咸阳712000 [2]陕西中医药大学附属医院肿瘤医院二病区

出　　处：《山西医药杂志》2024年第3期169-173,共5页Shanxi Medical Journal

基　　金：陕西省自然科学基础研究计划项目(S2021-JC-YB-0322)。

摘　　要：目的 探究血清白细胞介素-35(IL-35)表达水平与前列腺癌全雄激素阻断(MAB)患者预后的相关性。方法 收集2017年4月至2020年4月在本院接受MAB治疗的60例前列腺癌患者为研究对象。测定患者治疗前血清IL-35水平。依据随访结果,用受试者工作特征(ROC)曲线确定IL-35最佳截断值,并以此将纳入者分为低IL-35组和高IL-35组。比较2组病理特征,Kaplan-Meier生存曲线和Cox回归模型分析血清IL-35与患者预后的相关性。结果 以3年随访是否死亡为结局绘制ROC曲线,所得IL-35最佳截断值147.73 pg/ml[曲线下面积(95%CI)=0.667(0.517,0.818,P<0.001)],并以此为临界点将患者分为低IL-35组(<147.73 pg/ml)和高IL-35组(≥147.73 pg/ml)。高IL-35组中Gleason评分>7分(58%和29%)、肿瘤T分期中T4期(74%和44%)和伴淋巴结转移(68%和39%)者占比均显著高于低IL-35组(P<0.05)。KaplanMeier生存曲线显示,低IL-35组患者无进展生存(PFS)[(32±4)个月和(23±4)个月]和总生存[(32±3)个月和(24±4)个月]情况均优于高IL-35组患者(χ^(2)=11.988、8.617,P<0.05);单因素和多因素Cox回归模型分析显示,血清IL-35水平[HR值(95%CI)=1.044 (1.017,1.073)]、[HR值(95%CI)=1.035(1.006,1.064)];Gleason评分[HR值(95%CI)=2.218 (1.449,6.307)]、[HR值(95%CI)=3.056 (1.649,9.447)];临床T分期[HR值(95%CI)=2.056(1.553,5.984)]、[HR值(95%CI)=1.900(1.237,11.622)]和伴淋巴结转移[HR值(95%CI)=2.415(2.084,7.445)]、[HR值(95%CI)=4.147(1.081,15.910)]均是影响MAB治疗的前列腺癌患者无进展生存期(PFS)和总生存情况的独立危险因素(P<0.05)。结论 治疗前血清IL-35水平异常升高是影响前列腺癌患者MAB治疗预后的独立危险因素。Objective To investigate the correlation between the expression level of serum interleukin(IL)-35 and the prognosis of prostate cancer patients with total androgen blockade(MAB).Methods Sixty prostate cancer patients who received MAB treatment in our hospital from April 2017 to April 2020 were collected as research objects.The serum IL-35 level of patients before treatment was measured.According to the follow-up results,the receiver operating characteristic curve(ROC)was used to determine the optimal cut-off value of IL-35,and then the participants were divided into low IL-35 group and high IL-35 group.The pathological characteristics of the two groups were compared,and the Kaplan-Meier survival curve and Cox regression model were used to analyze the correlation between serum IL-35 and the prognosis of patients.Results The ROC curve was drawn with a 3-year follow-up as the outcome,and the best cut-off value of IL-35 was 147.73 pg/ml[area under the curve(95%CI)0.667(0.517,0.818,P<0.001)],and this was taken as the critical point to divide the patents into low IL-35 group(<147.73 pg/ml)and high IL-35 group(≥147.73pg/ml).In the high IL-35 group,the proportions of Gleason score>7 points(58%vs 29%),T4 stage(74%vs 44%)and lymph node metastasis(68%vs 39%)in T stage were significantly higher than those in the low IL-35 group(P<0.05).The Kaplan-Meier survival curve showed that the progression-free survival(PFS)[(32±4)months vs(23±4)months]and overall survival[(32±3)months vs(24±4)months]of patients in the low IL-35 group were significantly better than those in the high IL-35 group(P<0.05).Univariate and multivariate Cox regression model analysis showed that serum IL-35 level[HR(95%CI)=1.044(1.017,1.073)]、[HR(95%CI)=1.035(1.006,1.064)];Gleason score[HR(95%CI)=2.218(1.449,6.307)]、[HR(95%CI)=3.056(1.649,9.447)];clinical T stage[HR(95%CI)=2.056(1.553,5.984)]、[HR(95%CI)=1.900(1.237,11.622)]and lymph node metastasis[HR(95%CI)=2.415(2.084,7.445)]、[HR(95%CI)=4.147(1.081,15.910)]were independent risk factors for PFS a

关 键 词：前列腺癌 全雄激素阻断 预后 白细胞介素-35 相关性 

分 类 号：R737.25[医药卫生—肿瘤]